People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AIT Therapeutics, Inc. | — | Biotechnology | Series B | $77.5M | $132.7M | 2023 |
Douglas Quinton Larson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Douglas Quinton Larson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerome Zeldis | 1 | 6 |
| Jerome B. Zeldis | 1 | 5 |
| Ron Bentsur | 1 | 4 |
| David Grossman | 1 | 4 |
| William P. Forbes | 1 | 3 |
| Racheli Vizman | 1 | 2 |
| Steven A. Lisi | 1 | 2 |
| Steven Lisi | 1 | 2 |
| Amir Avniel | 1 | 2 |
| Ari Raved | 1 | 2 |
| Yossef Av-Gay | 1 | 2 |
| Ron Lynn Bentsur | 1 | 1 |
| Jeff Lynn Myers | 1 | 1 |
| Robert Lynn Carey | 1 | 1 |
| Lee Yoori | 1 | 1 |
| Forbes William | 1 | 1 |
| Bentsur Ron | 1 | 1 |
| Carey Robert | 1 | 1 |
| Avniel Amir | 1 | 1 |
| Beck Douglas | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.